ArticleThe Laryngoscope2026
National Trends in Thyroidectomy and Molecular Diagnostic Utilization: A Medicare Analysis (2016-2023).
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAs healthcare expenditures rise, characterizing the national utilization and economic footprint of genomic sequencing classifiers (GSCs) for indeterminate thyroid nodules is essential. We evaluated adoption trends and Medicare spending for primary GSC platforms (Afirma, ThyroSeq, and ThyGeNEXT/ThyraMIR) over 8 years.
methodsWe conducted a retrospective analysis of Medicare Part B Provider Utilization and Payment data (2016-2023). GSC and surgical services were identified via CPT codes. Medicare payments were adjusted to 2016 U.S. dollars using the Medical Care Consumer Price Index. Trends were evaluated using linear regression.
resultsTotal GSC utilization increased from 4478 services in 2016 to 13,456 in 2023 (200.5% increase). GSC adoption as percentage of fine-needle aspirations increased from 2.11% to 7.71% (p < 0.001). Afirma was the primary driver, increasing from 4478 to 9273 services (p < 0.001). Following the introduction of Proprietary Laboratory Analyses codes, ThyroSeq and ThyGeNEXT/ThyraMIR demonstrated rapid uptake, reaching 509 and 3674 annual services by 2023, respectively. Concurrent with increased GSC adoption, total thyroidectomy procedures declined 42.1% (p < 0.001), while lobectomy procedures decreased 20.7% (p = 0.006), indicating surgical de-escalation. Inflation-adjusted Medicare expenditures for GSCs rose significantly from $14.0 million to $35.3 million (p = 0.002), but average adjusted payment per Afirma test remained stable ($2963-$3366, p = 0.218).
conclusionThis Medicare-based national analysis demonstrates GSC utilization tripled from 2016 to 2023, temporally associated with substantial surgical de-escalation. This population-level correlation may reflect the clinical impact of molecular diagnostics in reducing potentially unnecessary thyroid surgery. Expenditure growth was driven by adoption rather than price inflation. LEVEL OF EVIDENCE: N/A.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.